| Zestra(TM) Female
Arousal Fluid Provides Solution for Many Female
Sexual Problems; Pfizer Ends Research of Viagra(R)
for Women
March 09, 2004
QualiLife Pharmaceuticals' Receives 'Notice
of Allowance of United States Patent' on Zestra(TM)
for Women / Zestra(TM) Female Arousal Fluid
CHARLESTON, S.C., March 9 /PRNewswire/ -- The
only clinically-proven topical Female Arousal
Fluid Zestra(TM) has received "Notice of
Allowance" from the United States Patent
and Trademark Office just as Pfizer (NYSE: PFE
- News) announced its decision to end Viagra
research in women. QualiLife Pharmaceuticals,
Inc., a privately-held consumer products company
focused on Women's Health, has been developing
Zestra since 1997.
(Photo: http://www.newscom.com/cgi-bin/prnh/20040309/CLTUFNS1
)
The non-prescription Zestra patent is titled
"Compositions and Method for Enhancing
or Treating Female Sexual Response". Zestra
from QualiLife Pharmaceuticals has demonstrated
robust increases in female sexual arousal, pleasure
and satisfaction in a well-designed, well-controlled
clinical study conducted by several leading
independent sexual
medicine experts and scientists. The randomized,
double-blind, placebo-controlled, crossover
clinical study results are published in numerous
respected medical journals. See: www.zestraforwomen.com
"The approval of the Zestra patent is
another milestone in QualiLife's strategy of
utilizing safe, effective bioactives from scientifically
researched botanicals to provide clinically
proven solutions for women", says pharmaceutical
scientist and sexual medicine expert, Martin
G. Crosby, R.Ph., its inventor. International
patents are pending.
Of the three highly-effective oral "prescription-only"
male erectile
dysfunction (ED) drugs; Viagra,
Levitra and Cialis, and the other prescription-based
products that are presently in clinical trials
intended for women's sexual complaints -- all
were originally designed for use in men. Since
1996, several pharmaceutical companies have
tried to adapt the "male" prescription
ED drugs for use in female sexual complaints,
but have met with little to no success in women
since their pharmacologic mechanism of action
(PDE-V inhibition) solely involves increasing
genital blood flow.
"It is surprising that it took Pfizer
eight years and 3,000 women to finally announce
their decision last week," says Zestra's
inventor. "Our research team knew in 1997
that the pharmaceutical companies were headed
in the wrong direction for women with testing
of any PDE-V inhibitor used alone". Instead,
we focused our pharmacologic and natural product
expertise on the desired goal of increasing
female sexual pleasure and satisfaction which
required a novel and more complex approach".
Published Clinical Study
Clinical study results for Zestra were first
reported in Boston at the prestigious International
Society for the Study of Women's Sexual Health
(ISSWSH) and results are published in several
respected medical journals -- The Journal of
Sex & Marital Therapy, Drugs, National Association
of Nurse Practitioners in Women's Health (NPWH)
-- Women's Health Care: A Practical Journal
for Nurse Practitioners, and WebMD Medical News.
http://www.zestraforwomen.com/aboutzestra/publications.html
Zestra Female Arousal Fluid will be available
in retail pharmacies nationwide in May 2004
and easily located in the "Family Planning"
sections and/or 'Women's Personal Care' sections.
It is already available by purchasing online
at the "Official Zestra for Women Website":
www.zestraforwomen.com or by calling (1-877-4-ZESTRA)(1-877-493-7872)
Monday - Friday from 9am to 5pm Eastern Time.
The Zestra Advantage
Only Zestra was designed by pharmaceutical
scientists and women's sexual
health experts to effectively address the
sexual pleasure pathways that are specific to
women, says Crosby. "Non-prescription Zestra
is the natural solution for most women who experience
sexual problems such as difficulty with
arousal, lubrication, sensation, pleasure, orgasm
and satisfaction".
Women without sexual difficulties are embracing
Zestra as the ultimate "Women's Lifestyle
Product" for seeking sexual satisfaction.
No other women's product has been proven to
be more effective at increasing sexual pleasure,
Crosby says. Applied during foreplay, the gentle
application of Zestra combined with tender massage
also helps to lubricate and arouse delicate
tissue.
Prescription drugs using the nitric oxide pathway
alone (Viagra, Levitra and Cialis)
all work well in men with ED, but increased
genital blood flow by itself, does not correlate
well with increased female sexual pleasure as
it (nitric oxide) is not involved in sexual
sensation. "Accordingly, the inconclusive
results obtained from studies of Viagra-type
drugs by pharmaceutical companies attempting
to develop a potential "FDA- approved treatment
for female sexual arousal disorder (FSAD), a
common type of female sexual dysfunction (FSD)"
has confounded many sexual medicine researchers
over the years -- but QualiLife's scientists
knew the solution for women was not going to
be that simple" says Crosby.
Women Are Much More Complex
While Pfizer started the ED sexual revolution,
with its Viagra product for men, they recently
suspended Viagra research on the female
sexual dysfunction market, as studies on women
proved inconclusive. There are still no prescription
drugs that are FDA-approved to treat any form
of Female Sexual Dysfunction (FSD) or help with
female sexual pleasure and sexual satisfaction.
Non-prescription Zestra(TM) is the only clinically
proven solution for women seeking an effective
product that lubricates while safely increasing
female arousal and sexual pleasure.
Competitive Landscape
Topical: While other non-prescription topical
products may claim to increase female pleasure
-- none are supported by a well-designed, well-controlled
clinical study that has been conducted by independent
recognized sexual medicine experts. None of
those products are published in the medical
or scientific literature. Other topical products
on the market simply use known "chemical
irritants" to produce sensation by irritating
delicate clitoral and vaginal tissue. (examples
are -- menthol, orange oil, peppermint oil,
etc). Unfortunately, most of those products
also contain L-Arginine, which can re-activate
an outbreak of genital herpes.
Oral: One widely marketed herbal pill, Avlimil,
has as its primary listed ingredient Salvia.
Numerous Safety Warnings concerning Avlimil
have been published in physician, pharmacy and
nursing journals advising healthcare professionals
about the known neurotoxins in Salvia which
can cause systemic side effects such as nausea,
vomiting & hallucinations due to its thujone
and isothujone content. Informed healthcare
professionals are aware of these potentially
serious risks and are advising their patients
not to take that product.
QualiLife's Strategic Focus
QualiLife is a Specialty Consumer Products
company focused on satisfying large unmet needs
by leveraging its proprietary research platform
combined with pharmaceutical expertise in natural
flavinoid technologies, biological precursor
technologies, together with incorporation of
highly-researched botanical bioactives having
scientifically established activities and well-documented
favorable safety profiles. While Zestra is QualiLife's
flagship product, the Company has additional
promising consumer products in late-stage development
that address other large unmet needs in Women's
Health. QualiLife's proprietary targeted female
libido solution is expected to join Zestra in
the Company's consumer product line in October
2004. The Company continues to remain focused
in Women's Health and will seek commercialization
partners while exploring financing and/or merger
options to maximize the Zestra and other pipeline
opportunities.
source:-http://biz.yahoo.com
|
